---
title: "Breast Surgery"
order: 2
category: "General Surgery"
---

# Breast Surgery

## Overview

Breast surgery encompasses both benign and malignant conditions of the breast. Surgical management ranges from minimally invasive biopsies to oncologic procedures including breast-conserving surgery and mastectomy. A multidisciplinary approach involving surgeons, medical oncologists, radiation oncologists, radiologists, and pathologists ensures optimal patient care.

## Breast Cancer Surgery

### Indications

#### Breast Cancer Diagnosis

**Clinical Presentation**
- **Palpable Mass**: Firm, irregular, fixed to surrounding tissue
- **Skin Changes**: Dimpling, peau d'orange, erythema
- **Nipple Changes**: Retraction, discharge (especially bloody)
- **Axillary Lymphadenopathy**: Palpable nodes
- **Inflammatory Signs**: Erythema, warmth (inflammatory breast cancer)

**Diagnostic Workup**
- **Triple Assessment**:
  1. Clinical examination
  2. Imaging (mammography, ultrasound, MRI)
  3. Tissue diagnosis (core needle biopsy)

- **Biopsy Methods**:
  - **Core Needle Biopsy** (Preferred): 14-16 gauge, 3-5 cores
  - **Fine Needle Aspiration**: Limited use, cytology only
  - **Excisional Biopsy**: Diagnostic and therapeutic for small lesions

**Pathologic Classification**
- **Invasive Ductal Carcinoma (IDC)**: 70-80% of breast cancers
- **Invasive Lobular Carcinoma (ILC)**: 10-15%, often multifocal
- **Ductal Carcinoma In Situ (DCIS)**: Non-invasive, high-grade requires surgery
- **Special Types**: Mucinous, tubular, medullary (better prognosis)

**Receptor Status** (Guides treatment)
- **Estrogen Receptor (ER)**: Positive in 70-80%
- **Progesterone Receptor (PR)**: Positive in 65%
- **HER2**: Overexpressed/amplified in 15-20%
- **Triple Negative**: ER-, PR-, HER2- (10-15%, worse prognosis)

#### Staging

**TNM Classification (AJCC 8th Edition)**

**Primary Tumor (T)**
- **Tis**: Carcinoma in situ (DCIS)
- **T1**: ≤20 mm (T1mi ≤1 mm, T1a 1-5 mm, T1b 6-10 mm, T1c 11-20 mm)
- **T2**: 21-50 mm
- **T3**: >50 mm
- **T4**: Chest wall or skin involvement

**Regional Lymph Nodes (N)**
- **N0**: No regional lymph node metastasis
- **N1**: 1-3 axillary nodes or internal mammary nodes
- **N2**: 4-9 axillary nodes
- **N3**: ≥10 axillary nodes or infraclavicular nodes

**Distant Metastasis (M)**
- **M0**: No distant metastasis
- **M1**: Distant metastasis present

**Stage Grouping**
- **Stage 0**: Tis N0 M0 (DCIS)
- **Stage I**: T1 N0 M0
- **Stage IIA**: T0-1 N1 M0 or T2 N0 M0
- **Stage IIB**: T2 N1 M0 or T3 N0 M0
- **Stage IIIA**: T0-2 N2 M0 or T3 N1-2 M0
- **Stage IIIB**: T4 N0-2 M0
- **Stage IIIC**: Any T N3 M0
- **Stage IV**: Any T Any N M1

### Preoperative Assessment

#### Clinical Evaluation
- **Patient History**: Family history (BRCA mutations), prior breast disease
- **Physical Examination**: Tumor size, location, fixation, skin changes
- **Axillary Assessment**: Palpable lymphadenopathy
- **Bilateral Examination**: Contralateral breast assessment
- **Performance Status**: Fitness for surgery and adjuvant therapy

#### Imaging Studies

**Mammography**
- **Diagnostic Bilateral**: Evaluate extent, multifocality
- **Findings**: Mass, calcifications, architectural distortion
- **BI-RADS Classification**: 0-6 scale

**Breast Ultrasound**
- **Primary Mass**: Characterization (solid vs. cystic)
- **Axillary Nodes**: Suspicious features (cortical thickening, loss of fatty hilum)
- **Biopsy Guidance**: Real-time visualization

**Breast MRI**
- **High-Risk Patients**: BRCA carriers, dense breasts
- **Preoperative Planning**: Assess extent, multifocality, contralateral disease
- **Neoadjuvant Therapy**: Monitor response
- **Limitations**: High sensitivity, lower specificity (many false positives)

**Staging Studies** (For advanced disease)
- **CT Chest/Abdomen/Pelvis**: Assess metastasis
- **Bone Scan**: Bone metastases (if symptoms or elevated alkaline phosphatase)
- **PET-CT**: Selected cases, locally advanced or recurrent disease

#### Laboratory Studies
- **Complete Blood Count**: Baseline
- **Comprehensive Metabolic Panel**: Liver function
- **Tumor Markers**: CEA, CA 15-3, CA 27-29 (baseline, not diagnostic)
- **Genetic Testing**: BRCA1/2 if family history or young age (<50)

#### Multidisciplinary Conference
- **Participants**: Surgeon, medical oncologist, radiation oncologist, radiologist, pathologist
- **Discussion**: Surgical options, neoadjuvant vs. adjuvant therapy, reconstruction timing
- **Treatment Plan**: Personalized approach based on tumor biology and patient factors

### Surgical Techniques

#### Breast-Conserving Surgery (BCS) / Lumpectomy

**Patient Selection**
- **Tumor Size**: Generally <5 cm (relative to breast size)
- **Unifocal Disease**: Single tumor focus
- **No Contraindications**: See below
- **Patient Preference**: Desire for breast preservation

**Contraindications to BCS**
- **Absolute**:
  - Diffuse malignant microcalcifications
  - Prior radiation to breast/chest wall
  - Positive margins after reasonable attempts
  - Pregnancy (if radiation would be delayed)
- **Relative**:
  - Multiple tumors in different quadrants
  - Large tumor-to-breast ratio (poor cosmesis expected)
  - Patient preference for mastectomy

**Operative Technique**

**Preoperative Localization** (Non-palpable lesions)
- **Wire Localization**: Radiologist-placed guide wire
- **Radioactive Seed**: Iodine-125 seed placed days before surgery
- **Radar Reflector (SAVI SCOUT)**: Wireless localization
- **Magnetic Seed**: Magseed technology

**Incision Planning**
- **Location**: Over or near tumor
- **Direction**: Follow Langer's lines (cosmesis)
- **Oncoplastic Principles**: Volume displacement or replacement

**Surgical Steps**
1. **Skin Incision**: Preserve skin, adequate access
2. **Tumor Excision**: Wide local excision with margin
3. **Specimen Orientation**: Mark with sutures/clips (superior, lateral, etc.)
4. **Cavity Markers**: Surgical clips mark lumpectomy bed (for radiation)
5. **Specimen Imaging**: Intraoperative specimen radiograph
6. **Margin Assessment**: Gross examination, send cavity shavings if close
7. **Hemostasis**: Meticulous, minimize seroma risk
8. **Closure**: Layered closure, preserve breast contour

**Margin Assessment**
- **Negative Margin Definition**: No ink on tumor (DCIS and invasive)
- **Intraoperative Assessment**: Gross examination, frozen section rarely helpful
- **Final Pathology**: Dictates need for re-excision
- **Re-excision Rate**: 15-30% in many series

**Oncoplastic Techniques**
- **Volume Displacement**: Breast reduction/mastopexy patterns
- **Volume Replacement**: Flaps (latissimus dorsi, thoracodorsal artery perforator)
- **Symmetry Procedures**: Contralateral breast surgery for balance
- **Benefits**: Improved cosmesis, ability to excise larger volumes

#### Mastectomy

**Types of Mastectomy**

**Simple/Total Mastectomy**
- **Tissue Removed**: All breast tissue, nipple-areola complex
- **Axilla**: No axillary dissection (level I nodes may be included)
- **Indications**: DCIS, prophylactic, some invasive cancers with negative nodes

**Modified Radical Mastectomy (MRM)**
- **Tissue Removed**: All breast tissue, NAC, level I-II axillary nodes
- **Muscles Preserved**: Pectoralis major and minor
- **Indications**: Invasive cancer, multiple positive nodes, patient preference

**Skin-Sparing Mastectomy (SSM)**
- **Tissue Removed**: Breast tissue, NAC
- **Skin Preserved**: Breast skin envelope (except NAC)
- **Reconstruction**: Immediate reconstruction (implant or autologous)
- **Oncologic Safety**: Equivalent to traditional mastectomy for appropriate candidates

**Nipple-Sparing Mastectomy (NSM)**
- **Tissue Removed**: Breast tissue only
- **Preserved**: Skin envelope and nipple-areola complex
- **Selection Criteria**: Tumor >2 cm from NAC, no nipple involvement
- **Intraoperative**: Frozen section of retroareolar tissue
- **Reconstruction**: Immediate reconstruction, superior cosmesis

**Operative Technique (Modified Radical Mastectomy)**

**Incision**
- **Type**: Elliptical, encompassing nipple-areola complex
- **Previous Biopsy Scars**: Incorporate if feasible
- **Reconstruction Planning**: Coordinate with plastic surgeon

**Surgical Steps**
1. **Skin Flap Development**:
   - Superior: Clavicle
   - Inferior: Inframammary fold
   - Medial: Midline
   - Lateral: Latissimus dorsi border
   - **Thickness**: Subcutaneous fat preserved, breast tissue removed

2. **Medial Dissection**: Pectoralis major fascia

3. **Superior Dissection**: Clavicle and subclavius

4. **Lateral Dissection**: Latissimus dorsi border

5. **Inferior Dissection**: Inframammary fold

6. **Axillary Dissection**:
   - Divide pectoralis minor insertion or retract medially
   - Identify axillary vein (superior border)
   - Dissect level I-II nodes
   - Preserve long thoracic nerve (serratus anterior)
   - Preserve thoracodorsal nerve and vessels (latissimus dorsi)
   - Identify and preserve intercostobrachial nerve if possible

7. **Specimen Removal**: En bloc breast and axillary contents

8. **Hemostasis**: Meticulous, minimize seroma

9. **Drain Placement**: Closed suction drains (1-2)

10. **Closure**: Layered, drains exit lateral/inferior

**Skin-Sparing/Nipple-Sparing Modifications**
- **Incisions**: Inframammary, periareolar, lateral
- **Flap Thickness**: Thin but well-perfused
- **Immediate Reconstruction**: Coordinate with plastic surgeon
- **Nipple Preservation**: Assess viability, frozen section of retroareolar tissue

#### Sentinel Lymph Node Biopsy (SLNB)

**Indications**
- **Clinically Node-Negative**: No palpable or imaging-suspected nodes
- **Primary Tumor**: T1-T2, selected T3
- **Post-Neoadjuvant**: If initially node-negative (dual mapping recommended)

**Contraindications**
- **Clinically Node-Positive**: Proceed directly to ALND
- **Inflammatory Breast Cancer**: Contraindication
- **Pregnancy**: Radioisotope relatively contraindicated (blue dye safe)

**Mapping Techniques**
- **Radioisotope (Technetium-99m)**:
  - Injection: Periareolar, peritumoral, or subareolar
  - Timing: 1-4 hours preoperatively or day before
  - Detection: Gamma probe intraoperatively

- **Blue Dye (Isosulfan Blue, Methylene Blue)**:
  - Injection: Subareolar or peritumoral
  - Timing: 5-10 minutes before incision
  - Visualization: Blue-stained lymphatics and nodes
  - Caution: Allergic reactions (1%), transient blue skin/urine

- **Dual Technique** (Preferred): Radioisotope + blue dye (highest identification rate)

- **Indocyanine Green (ICG)**: Fluorescence imaging, increasing use

**Operative Technique**
1. **Mapping Agent Injection**: Per protocol
2. **Incision**: Separate axillary incision or through mastectomy incision
3. **Gamma Probe**: Identify "hot" nodes (>10% of hottest node)
4. **Visual Identification**: Blue-stained nodes
5. **Palpation**: Firm/suspicious nodes
6. **Removal**: Typically 1-3 SLNs
7. **Ex Vivo Count**: Confirm radioactivity
8. **Background Count**: Ensure removal of all "hot" nodes (<10% of SLN)

**Pathologic Assessment**
- **Frozen Section**: Not routinely recommended (high false negative)
- **Permanent Section**: H&E, immunohistochemistry (cytokeratin)
- **Isolated Tumor Cells (ITC)**: <0.2 mm, N0(i+)
- **Micrometastasis**: 0.2-2 mm, N1mi
- **Macrometastasis**: >2 mm, N1

**Success Metrics**
- **Identification Rate**: >95% with dual technique
- **False Negative Rate**: 5-10%
- **Sensitivity**: 90-95% for detecting axillary metastases

#### Axillary Lymph Node Dissection (ALND)

**Indications**
- **Positive SLNB**: Traditional indication (now selective)
- **Clinically Node-Positive**: Palpable or biopsy-proven metastasis
- **Failed SLNB**: Unable to identify sentinel nodes

**Modern De-escalation**
- **ACOSOG Z0011 Trial**: BCS + RT + systemic therapy, 1-2 positive SLNs, no ALND
- **AMAROS Trial**: SLNB-positive, axillary RT vs. ALND, equivalent outcomes
- **Current Practice**: Selective ALND based on tumor biology, treatment plan

**Operative Technique**
1. **Incision**: Transverse incision inferior to axillary hairline
2. **Boundaries**:
   - **Medial**: Lateral border of pectoralis minor (level I-II dissection)
   - **Lateral**: Latissimus dorsi
   - **Superior**: Axillary vein
   - **Inferior**: Intercostobrachial nerves

3. **Level I**: Lateral to pectoralis minor
4. **Level II**: Behind pectoralis minor
5. **Level III**: Medial to pectoralis minor (rarely dissected)

6. **Nerve Preservation**:
   - **Long Thoracic Nerve**: Runs on serratus anterior, preserve (winged scapula)
   - **Thoracodorsal Nerve**: Innervates latissimus dorsi, preserve
   - **Intercostobrachial Nerves**: Sensory to upper inner arm, preserve if possible

7. **Yield**: Typically 10-30 nodes removed

8. **Drain Placement**: Closed suction drain

**Complications**
- **Lymphedema**: 10-30% (vs. 5% with SLNB alone)
- **Seroma**: 30-50%
- **Sensory Changes**: Intercostobrachial nerve injury (medial arm numbness)
- **Limited Shoulder Mobility**: 10-20%, physical therapy important

### Postoperative Management

#### Immediate Postoperative Care

**Recovery Room**
- **Hemodynamic Monitoring**: Blood pressure, heart rate
- **Drain Management**: Monitor output
- **Pain Control**: Multimodal analgesia
- **Nausea Prevention**: Antiemetics

**Hospital Stay**
- **Lumpectomy**: Same-day discharge typical
- **Mastectomy**: Overnight or 23-hour observation common
- **Reconstruction**: 1-3 days depending on technique

#### Drain Management
- **Output Monitoring**: Record daily drainage
- **Removal Criteria**: <30 mL/day for 2 consecutive days
- **Duration**: Typically 7-14 days
- **Complications**: Seroma formation if premature removal

#### Pain Management
- **Multimodal Approach**:
  - Acetaminophen 1000 mg q6h scheduled
  - NSAIDs (if no contraindications)
  - Opioids: minimal, short-acting for breakthrough
- **Nerve Blocks**: Paravertebral, pectoralis blocks (PECS I/II)
- **Avoid**: Chronic opioid use (risk of dependence)

#### Wound Care
- **Dressing**: Keep clean and dry for 48 hours
- **Showering**: After 48 hours, pat dry
- **Suture/Staple Removal**: 7-14 days (if non-absorbable)
- **Incision Care**: Signs of infection (erythema, drainage, fever)

#### Activity Restrictions
- **Arm Mobility**: Gentle range of motion immediately
- **Heavy Lifting**: Avoid >10 lbs for 2-4 weeks
- **Driving**: When off narcotics and full arm mobility
- **Exercise**: Gradual return, no restrictions by 6 weeks
- **Physical Therapy**: For limited shoulder mobility (especially post-ALND)

#### Follow-up

**Short-term (2 weeks)**
- **Wound Check**: Healing assessment
- **Drain Management**: Removal if criteria met
- **Pathology Review**: Final staging, margin status
- **Adjuvant Therapy Planning**: Referrals to medical and radiation oncology

**Long-term Surveillance**
- **Physical Examination**: Every 3-6 months for 3 years, then annually
- **Mammography**: Annual ipsilateral (if BCS), contralateral
- **Breast MRI**: High-risk patients (BRCA, prior chest radiation)
- **Laboratory**: Not routinely recommended (tumor markers)
- **Imaging**: Only if symptoms suggest recurrence

### Complications

#### Intraoperative Complications
- **Bleeding** (2-5%): Thoracodorsal, lateral thoracic vessels
- **Nerve Injury** (<1%): Long thoracic, thoracodorsal (usually traction)
- **Pneumothorax** (<1%): Apical dissection

#### Early Postoperative Complications (0-30 days)

**Seroma** (30-85% mastectomy)
- **Presentation**: Fluid collection under flaps
- **Prevention**: Drains, quilting sutures, tissue sealants
- **Management**: Observation, aspiration if large/symptomatic
- **Resolution**: Usually spontaneous over weeks

**Hematoma** (1-5%)
- **Presentation**: Acute swelling, pain, may be expanding
- **Management**: Small/stable (observation), large/expanding (evacuation)
- **Prevention**: Meticulous hemostasis, blood pressure control

**Wound Infection** (3-15%)
- **Risk Factors**: Obesity, diabetes, smoking, reconstruction
- **Presentation**: Erythema, warmth, drainage, fever
- **Management**: Antibiotics (staph/strep coverage), drainage if abscess
- **Severe**: May compromise reconstruction

**Skin Flap Necrosis** (5-30% NSM)
- **Risk Factors**: Thin flaps, smoking, radiation, previous surgery
- **Prevention**: Adequate flap thickness, avoid tension
- **Management**: Local wound care, debridement if needed, may delay reconstruction

**Lymphedema** (Arm swelling)
- **Incidence**: 5-10% SLNB, 20-40% ALND
- **Risk Factors**: Axillary dissection, radiation, obesity, infection
- **Prevention**: Avoid arm BP/venipuncture on affected side, exercise, weight control
- **Management**: Compression garments, manual lymphatic drainage, physical therapy

#### Late Complications (>30 days)

**Chronic Pain** (Post-Mastectomy Pain Syndrome, 20-50%)
- **Types**: Neuropathic (intercostobrachial injury), phantom breast pain
- **Management**: Gabapentin, pregabalin, duloxetine, physical therapy
- **Severe**: Pain clinic referral

**Shoulder Dysfunction** (10-30%)
- **Causes**: ALND, radiation, frozen shoulder
- **Prevention**: Early physical therapy, range of motion exercises
- **Treatment**: Physical therapy, NSAIDs

**Cosmetic Issues**
- **Asymmetry**: Size, shape differences
- **Breast Distortion**: After BCS, especially large excisions
- **Management**: Oncoplastic revision, contralateral symmetry procedure

**Psychological**
- **Body Image**: Changes after mastectomy
- **Depression/Anxiety**: 20-30% of patients
- **Sexual Dysfunction**: Related to body image, treatment effects
- **Support**: Counseling, support groups, psychiatric referral if needed

### Outcomes

#### Oncologic Outcomes

**Breast-Conserving Surgery + Radiation**
- **Local Recurrence**: 5-10% at 10 years
- **Overall Survival**: Equivalent to mastectomy (multiple trials)
- **Disease-Free Survival**: Similar to mastectomy

**Mastectomy**
- **Local Recurrence**: 2-5% at 10 years
- **Chest Wall Recurrence**: Higher with T3/T4, positive margins, inflammatory

**Sentinel Lymph Node Biopsy**
- **Accuracy**: 95% sensitivity for detecting node-positive disease
- **Regional Recurrence**: <1% if SLNB negative
- **Axillary Control**: Equivalent to ALND in selected patients (Z0011)

#### Functional Outcomes

**Quality of Life**
- **BCS**: Better body image scores than mastectomy
- **NSM**: Better cosmesis and body image than SSM
- **Reconstruction**: Improves body image, but not to baseline

**Arm Function**
- **SLNB**: Minimal impact
- **ALND**: 10-20% significant shoulder dysfunction
- **Lymphedema**: Major impact on quality of life when present

**Sexual Function**
- **Impact**: Variable, related to body image and systemic therapy
- **BCS vs. Mastectomy**: Mixed results, individual variation

#### Patient Satisfaction
- **BCS**: >85% satisfied with cosmesis
- **NSM with Reconstruction**: >90% satisfied
- **SSM with Reconstruction**: 80-85% satisfied
- **Mastectomy without Reconstruction**: 60-70% satisfied

## Benign Breast Disease

### Fibroadenoma

**Clinical Presentation**
- **Age**: Young women (15-30 years)
- **Characteristics**: Smooth, mobile, rubbery mass ("breast mouse")
- **Size**: 1-3 cm typically
- **Multiple**: 10-15% bilateral or multiple

**Diagnosis**
- **Triple Assessment**: Exam, imaging, biopsy
- **Ultrasound**: Well-circumscribed, hypoechoic, oval mass
- **Core Needle Biopsy**: Confirms diagnosis

**Indications for Excision**
- **Size >3 cm** (Giant fibroadenoma)
- **Enlarging**: Growth over 6 months
- **Patient Anxiety**: Desire for removal
- **Phyllodes Tumor Concern**: Rapid growth, imaging features

**Surgical Technique**
- **Incision**: Periareolar or radial (cosmetic)
- **Excision**: Shell out tumor, preserve normal tissue
- **Closure**: Layered, absorbable sutures

**Outcomes**
- **Recurrence**: 10-15% (new fibroadenomas, not true recurrence)
- **Cosmesis**: Generally excellent
- **Malignant Transformation**: Extremely rare

### Breast Cysts

**Clinical Presentation**
- **Age**: 30-50 years, uncommon after menopause
- **Characteristics**: Smooth, mobile, may be tender
- **Fluctuation**: Size varies with menstrual cycle

**Diagnosis**
- **Ultrasound**: Anechoic, well-circumscribed, posterior enhancement
- **Aspiration**: Diagnostic and therapeutic

**Management**
- **Simple Cysts**: No treatment needed unless symptomatic
- **Symptomatic**: Ultrasound-guided aspiration
- **Complex Cysts**: Core needle biopsy to rule out malignancy

**Indications for Surgery**
- **Recurrent**: After multiple aspirations
- **Complex Features**: Solid component, thick walls
- **Bloody Aspirate**: Concern for malignancy

### Mastitis and Breast Abscess

**Lactational Mastitis**
- **Presentation**: Erythema, warmth, tenderness, fever
- **Organism**: Staphylococcus aureus (including MRSA)
- **Management**: Antibiotics (dicloxacillin or cephalexin), continue breastfeeding

**Breast Abscess**
- **Presentation**: Fluctuant mass, fever, leukocytosis
- **Imaging**: Ultrasound confirms fluid collection
- **Management**:
  - **Small (<3 cm)**: Needle aspiration + antibiotics
  - **Large or Loculated**: Incision and drainage
  - **Recurrent**: May need excision

**Surgical Drainage**
- **Incision**: Radial (follows ducts) or periareolar
- **Breaking Loculations**: Digital or instrument
- **Packing**: Controversial, drain placement preferred
- **Closure**: Delayed primary or secondary intention

**Non-Lactational Abscess**
- **Periareolar**: Associated with squamous metaplasia of ducts
- **Recurrent**: May need excision of involved duct

### Papilloma

**Clinical Presentation**
- **Nipple Discharge**: Bloody or serosanguinous
- **Age**: 40-50 years
- **Location**: Central (solitary) vs. peripheral (multiple)

**Diagnosis**
- **Ductography**: Less commonly used
- **MRI**: High sensitivity for intraductal lesions
- **Ductoscopy**: Direct visualization
- **Core Biopsy**: Tissue diagnosis

**Indications for Surgery**
- **Symptomatic**: Persistent discharge
- **Atypical Cells**: On biopsy
- **Mass**: Palpable lesion

**Surgical Technique**
- **Duct Excision**: Remove affected duct system
- **Microdochectomy**: Single duct excision (if localized)
- **Central Duct Excision**: Multiple ducts (if diffuse)

**Pathology Concern**
- **Atypia**: 5-10% harbor atypia
- **Malignancy**: <5% associated with cancer

## Key Points

### Breast Cancer Surgery
- **Breast-conserving surgery** plus radiation has equivalent survival to mastectomy for early-stage breast cancer
- **Critical view of safety**: Negative margins (no ink on tumor) for invasive cancer and DCIS
- **Sentinel lymph node biopsy** is standard for clinically node-negative disease (>95% identification rate)
- **De-escalation of axillary surgery**: Selective ALND for SLNB-positive patients based on Z0011/AMAROS criteria
- **Oncoplastic techniques** improve cosmesis while maintaining oncologic safety
- **Nipple-sparing mastectomy** offers superior cosmesis with equivalent oncologic outcomes in selected patients
- **Multidisciplinary approach** essential for optimal breast cancer care

### Benign Breast Disease
- **Triple assessment** (clinical, imaging, biopsy) is standard for breast mass evaluation
- **Fibroadenomas** can be observed if <3 cm and not enlarging
- **Breast cysts** are managed with aspiration if symptomatic
- **Lactational mastitis** treated with antibiotics and continued breastfeeding; abscess requires drainage
- **Bloody nipple discharge** warrants surgical excision to rule out papilloma or malignancy

## References

1. **NCCN Clinical Practice Guidelines in Oncology: Breast Cancer** (Version 4.2024). National Comprehensive Cancer Network.

2. Giuliano AE, et al. **Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases (ACOSOG Z0011)**. Ann Surg. 2016;264(3):413-420.

3. Morrow M, et al. **Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ**. Ann Surg Oncol. 2016;23(12):3801-3810.

4. **American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 8th Edition** (2017). Springer.

5. Clough KB, et al. **Oncoplastic Breast Surgery: A Guide to Clinical Practice**. Springer, 2016.

6. De La Cruz L, et al. **Overall Survival, Disease-Free Survival, Local Recurrence, and Nipple-Areolar Recurrence in the Setting of Nipple-Sparing Mastectomy: A Meta-Analysis and Systematic Review**. Ann Surg Oncol. 2015;22(10):3241-3249.

7. Donker M, et al. **Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer (AMAROS Trial)**. Lancet Oncol. 2014;15(12):1303-1310.

8. **SSO-ASTRO Consensus Guideline on Margins for Breast-Conserving Surgery With Whole Breast Irradiation in Stage I and II Invasive Breast Cancer**. Int J Radiat Oncol Biol Phys. 2014;88(3):553-564.

9. Veronesi U, et al. **Twenty-Year Follow-up of a Randomized Study Comparing Breast-Conserving Surgery With Radical Mastectomy for Early Breast Cancer**. N Engl J Med. 2002;347(16):1227-1232.

10. **American Society of Breast Surgeons (ASBrS) Position Statements and Guidelines**: Consensus statements on margins, SLNB, oncoplastic surgery (2024).
